Simulations Plus (SLP)
NASDAQ:SLP
SLP Stock Chart & Stats
$11.43
-$4.39(-14.45%)
At close: 4:00 PM EST
$11.43
-$4.39(-14.45%)
Day’s Range― - ―
52-Week Range$11.09 - $36.45
Previous CloseN/A
Volume738.72K
Average Volume (3M)259.51K
Market Cap
$262.71M
Enterprise Value$237.49M
Total Cash (Recent Filing)$41.84M
Total Debt (Recent Filing)$508.00K
Price to Earnings (P/E)13.6
Beta1.22
Next Earnings
Jul 08, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding20,146,585
10 Day Avg. Volume394,171
30 Day Avg. Volume259,512
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.28
Price to Sales (P/S)3.60
P/FCF Ratio16.36
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.95
Enterprise Value/Gross Profit4.76
Enterprise Value/Ebitda14.12
Forecast
1Y Price Target
$23.50Price Target Upside105.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)1.04
Revenue Forecast (FY)$80.42M
Bulls Say, Bears Say
Bulls Say
Product Integration And AIPlans to improve product integration and expand AI and cloud capabilities aim to create a more seamless software ecosystem that could boost cross-selling and unlock new revenue streams.
Regulatory And Market TailwindsGrowing regulatory support for alternative scientific methods and rising biopharma demand for cost-effective drug development increase long-term demand for the company's biosimulation tools and enlarge the addressable market.
Revenue DriversStronger-than-expected results across revenue and profitability, together with backlog expansion and increased demand for development services, support clearer revenue visibility and potential for renewed growth.
Bears Say
Competitive And Growth ConcernsCompany has lagged several peers in revenue growth amid a highly competitive market, raising concerns about market share momentum while the stock trades at a premium to peers.
Earnings Guidance And Tax HeadwindLowered adjusted EPS guidance driven by a higher expected tax rate creates a headwind for per-share earnings despite management maintaining revenue and adjusted EBITDA outlooks.
Investor Visibility And Roadmap ClarityHigh-level investor presentation that did not quantify expected benefits of the product roadmap limits visibility on the roadmap's potential financial impact and leaves longer-term expectations unclear.
Simulations Plus News
SLP FAQ
What was Simulations Plus’s price range in the past 12 months?
Simulations Plus lowest stock price was $11.09 and its highest was $36.45 in the past 12 months.
What is Simulations Plus’s market cap?
Simulations Plus’s market cap is $262.71M.
When is Simulations Plus’s upcoming earnings report date?
Simulations Plus’s upcoming earnings report date is Jul 08, 2026 which is in 85 days.
How were Simulations Plus’s earnings last quarter?
Simulations Plus released its earnings results on Apr 09, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.03.
Is Simulations Plus overvalued?
According to Wall Street analysts Simulations Plus’s price is currently Undervalued.
Does Simulations Plus pay dividends?
Simulations Plus pays a Quarterly dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Simulations Plus dividends here
What is Simulations Plus’s EPS estimate?
Simulations Plus’s EPS estimate is 0.24.
How many shares outstanding does Simulations Plus have?
Simulations Plus has 20,146,585 shares outstanding.
What happened to Simulations Plus’s price movement after its last earnings report?
Simulations Plus reported an EPS of $0.35 in its last earnings report, beating expectations of $0.32. Following the earnings report the stock price went up 0.385%.
Which hedge fund is a major shareholder of Simulations Plus?
Currently, no hedge funds are holding shares in SLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Simulations Plus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.50 (105.60% Upside)
$23.50 (105.60% Upside)
Blogger Sentiment
Neutral
SLP Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 476.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.8%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.33%
12-Months-Change
Fundamentals
Return on Equity
-49.30%
Trailing 12-Months
Asset Growth
-27.28%
Trailing 12-Months
Company Description
Simulations Plus
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
SLP Company Deck
SLP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue growth (+8% YoY), strong adjusted EBITDA and margin expansion, increased services backlog, high software gross margins, and a solid balance sheet with $41.8M in cash and no debt. Strategic partnerships with three large pharma customers and continued AI integration represent meaningful long-term upside. Offsetting these positives were a pronounced decline in clinical operations revenue (–54%), lower trailing renewal rates (87% TTM), a materially higher effective tax rate (now 23–25%) reducing EPS, reduced other income, and management's deliberately conservative guidance due to macro fragility and limited near-term AI monetization. Overall, the encouraging growth, margins, cash position and strategic progress materially outweigh the notable but contained operational and tax headwinds.View all SLP earnings summariesSLP Stock 12 Month Forecast
Average Price Target
$23.50
▲(105.60% Upside)
Technical Analysis
Ownership Overview
17.39% Insiders
15.04% Mutual Funds
27.16% Other Institutional Investors
31.09% Public Companies and
Individual Investors